Grace Therapeutics, Inc. (GRCE) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
24/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseGRCE / S&P -50.97% / 15.20% |
LoseGRCE / S&P GRCE unavailable / 15.00% |
WinGRCE / S&P 51.95% / 50.40% |
| 2026-Q11/3 |
WinGRCE / S&P 33.82% / -4.33% |
LoseGRCE / S&P GRCE unavailable / 11.30% |
LoseGRCE / S&P -41.25% / 27.70% |
| 2025-Q41/3 |
WinGRCE / S&P 16.11% / 2.65% |
LoseGRCE / S&P GRCE unavailable / 9.00% |
LoseGRCE / S&P -73.28% / 13.40% |
| 2025-Q30/3 |
LoseGRCE / S&P 0.34% / 8.12% |
LoseGRCE / S&P GRCE unavailable / 4.61% |
LoseGRCE / S&P -47.52% / 13.45% |
| 2025-Q21/3 |
WinGRCE / S&P 30.26% / 10.94% |
LoseGRCE / S&P GRCE unavailable / 4.83% |
LoseGRCE / S&P -32.46% / 10.63% |
| 2025-Q10/3 |
LoseGRCE / S&P -39.04% / -4.27% |
LoseGRCE / S&P GRCE unavailable / 4.98% |
LoseGRCE / S&P -44.44% / 10.57% |
| 2024-Q41/3 |
WinGRCE / S&P 24.67% / 2.41% |
LoseGRCE / S&P GRCE unavailable / 5.25% |
LoseGRCE / S&P -77.21% / 6.15% |
| 2024-Q30/3 |
LoseGRCE / S&P 2.74% / 5.89% |
LoseGRCE / S&P GRCE unavailable / 5.89% |
LoseGRCE / S&P -81.30% / 6.11% |
| 2024-Q20/3 |
LoseGRCE / S&P -14.87% / 4.28% |
LoseGRCE / S&P GRCE unavailable / 5.38% |
LoseGRCE / S&P -79.75% / 5.12% |
| 2024-Q11/3 |
WinGRCE / S&P 18.69% / 10.56% |
LoseGRCE / S&P GRCE unavailable / 5.71% |
LoseGRCE / S&P -74.74% / 5.59% |
| 2023-Q41/3 |
LoseGRCE / S&P 3.96% / 11.69% |
LoseGRCE / S&P GRCE unavailable / 6.81% |
WinGRCE / S&P 178.14% / 7.78% |
| 2023-Q31/3 |
LoseGRCE / S&P -12.58% / -3.27% |
LoseGRCE / S&P GRCE unavailable / 7.52% |
WinGRCE / S&P 285.71% / -5.03% |
| 2023-Q22/3 |
WinGRCE / S&P 15.22% / 8.74% |
LoseGRCE / S&P GRCE unavailable / 9.50% |
WinGRCE / S&P 631.17% / -8.57% |
| 2023-Q11/3 |
LoseGRCE / S&P -8.00% / 7.50% |
LoseGRCE / S&P GRCE unavailable / 10.77% |
WinGRCE / S&P 1935.71% / -15.69% |
| 2022-Q40/3 |
LoseGRCE / S&P -13.79% / 7.56% |
LoseGRCE / S&P GRCE unavailable / 11.88% |
LoseGRCE / S&P GRCE unavailable / -17.99% |
| 2022-Q30/3 |
LoseGRCE / S&P -32.56% / -4.88% |
LoseGRCE / S&P GRCE unavailable / 13.47% |
LoseGRCE / S&P GRCE unavailable / -1.41% |
| 2022-Q20/3 |
LoseGRCE / S&P -29.51% / -16.10% |
LoseGRCE / S&P GRCE unavailable / 13.71% |
LoseGRCE / S&P GRCE unavailable / 11.04% |
| 2022-Q11/3 |
WinGRCE / S&P -3.17% / -4.60% |
LoseGRCE / S&P GRCE unavailable / 15.97% |
LoseGRCE / S&P GRCE unavailable / 42.23% |
| 2021-Q40/3 |
LoseGRCE / S&P -37.00% / 11.03% |
LoseGRCE / S&P GRCE unavailable / 15.00% |
LoseGRCE / S&P GRCE unavailable / 96.40% |
| 2021-Q30/3 |
LoseGRCE / S&P -55.36% / 0.58% |
LoseGRCE / S&P GRCE unavailable / 10.77% |
LoseGRCE / S&P GRCE unavailable / 69.42% |
| 2021-Q20/3 |
LoseGRCE / S&P -6.67% / 8.55% |
LoseGRCE / S&P GRCE unavailable / 6.58% |
LoseGRCE / S&P GRCE unavailable / 51.81% |
| 2021-Q11/3 |
WinGRCE / S&P 81.82% / 6.17% |
LoseGRCE / S&P GRCE unavailable / -1.06% |
LoseGRCE / S&P GRCE unavailable / 7.39% |
| 2020-Q41/3 |
WinGRCE / S&P 65.00% / 12.15% |
LoseGRCE / S&P GRCE unavailable / -3.72% |
LoseGRCE / S&P GRCE unavailable / -33.42% |
| 2020-Q30/3 |
LoseGRCE / S&P -57.45% / 8.93% |
LoseGRCE / S&P GRCE unavailable / -2.04% |
LoseGRCE / S&P GRCE unavailable / -27.10% |
| 2020-Q21/3 |
WinGRCE / S&P 23.68% / 20.54% |
LoseGRCE / S&P GRCE unavailable / -0.46% |
LoseGRCE / S&P GRCE unavailable / -27.11% |
| 2020-Q10/3 |
LoseGRCE / S&P -84.49% / -19.60% |
LoseGRCE / S&P GRCE unavailable / 3.47% |
LoseGRCE / S&P GRCE unavailable / -14.75% |
| 2019-Q41/3 |
WinGRCE / S&P 29.63% / 9.07% |
LoseGRCE / S&P GRCE unavailable / 5.36% |
LoseGRCE / S&P GRCE unavailable / 2.99% |
| 2019-Q31/3 |
WinGRCE / S&P 65.79% / 1.70% |
LoseGRCE / S&P GRCE unavailable / 5.02% |
LoseGRCE / S&P GRCE unavailable / 0.21% |
| 2019-Q21/3 |
WinGRCE / S&P 11.76% / 4.30% |
LoseGRCE / S&P GRCE unavailable / 6.64% |
LoseGRCE / S&P GRCE unavailable / 8.65% |
| 2019-Q11/3 |
WinGRCE / S&P 22.89% / 13.65% |
LoseGRCE / S&P GRCE unavailable / 8.12% |
LoseGRCE / S&P GRCE unavailable / 14.29% |
| 2018-Q40/3 |
LoseGRCE / S&P -35.66% / -13.52% |
LoseGRCE / S&P GRCE unavailable / 9.05% |
LoseGRCE / S&P GRCE unavailable / 18.23% |
| 2018-Q31/3 |
WinGRCE / S&P 126.32% / 7.71% |
LoseGRCE / S&P GRCE unavailable / 10.21% |
LoseGRCE / S&P GRCE unavailable / 19.06% |
| 2018-Q20/3 |
LoseGRCE / S&P -44.12% / 3.43% |
LoseGRCE / S&P GRCE unavailable / 9.03% |
LoseGRCE / S&P GRCE unavailable / 14.46% |
| 2018-Q11/3 |
WinGRCE / S&P 8.51% / -0.76% |
LoseGRCE / S&P GRCE unavailable / 7.68% |
LoseGRCE / S&P GRCE unavailable / 12.46% |
| 2017-Q40/3 |
LoseGRCE / S&P -33.80% / 6.64% |
LoseGRCE / S&P GRCE unavailable / 7.03% |
LoseGRCE / S&P GRCE unavailable / 13.82% |
| 2017-Q31/3 |
WinGRCE / S&P 7.58% / 4.48% |
LoseGRCE / S&P GRCE unavailable / 5.68% |
LoseGRCE / S&P GRCE unavailable / 17.57% |
| 2017-Q20/3 |
LoseGRCE / S&P -2.94% / 3.09% |
LoseGRCE / S&P GRCE unavailable / 4.83% |
LoseGRCE / S&P GRCE unavailable / 17.74% |
| 2017-Q11/3 |
WinGRCE / S&P 8.80% / 6.07% |
LoseGRCE / S&P GRCE unavailable / 3.67% |
LoseGRCE / S&P GRCE unavailable / 13.32% |
| 2016-Q40/3 |
LoseGRCE / S&P -30.17% / 3.82% |
LoseGRCE / S&P GRCE unavailable / 2.09% |
LoseGRCE / S&P GRCE unavailable / 7.05% |
| 2016-Q31/3 |
WinGRCE / S&P 29.71% / 3.85% |
LoseGRCE / S&P GRCE unavailable / 0.20% |
LoseGRCE / S&P GRCE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | GRCE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -28.71% | 20.78% |
| Annualized return | -28.71% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | GRCE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -85.88% | 83.14% |
| Annualized return | -32.40% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | GRCE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.62% | 319.30% |
| Annualized return | -28.73% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |